<VariationArchive VariationID="1705103" VariationName="NC_000001.10:g.(?_100652477)_(100661979_100671785)del" VariationType="Deletion" Accession="VCV001705103" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-06" DateCreated="2022-09-17" MostRecentSubmission="2022-09-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1699634" VariationID="1705103">
      <GeneList>
        <Gene Symbol="DBT" FullName="dihydrolipoamide branched chain transacylase E2" GeneID="1629" HGNC_ID="HGNC:2698" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p21.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="100186919" stop="100249834" display_start="100186919" display_stop="100249834" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="100652477" stop="100715408" display_start="100652477" display_stop="100715408" Strand="-" />
          </Location>
          <OMIM>248610</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000001.10:g.(?_100652477)_(100661979_100671785)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p21.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" innerStart="100652477" innerStop="100661979" outerStop="100671785" display_start="100652477" display_stop="100671785" variantLength="19309" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.(?_100652477)_(100661979_100671785)del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.(?_100652477)_(100661979_100671785)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000001.10:g.(?_100652477)_(100661979_100671785)del AND Maple syrup urine disease" Accession="RCV002283428" Version="1">
        <ClassifiedConditionList TraitSetID="6467">
          <ClassifiedCondition DB="MedGen" ID="C0024776">Maple syrup urine disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-09-17" MostRecentSubmission="2022-09-17">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">14508502</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14741190</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24304607</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33868929</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6467" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2822" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Maple syrup urine disease</ElementValue>
                <XRef ID="Maple+syrup+urine+disease/4453" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009563" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
                <XRef ID="511" DB="Orphanet" />
                <XRef ID="27718001" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MSUD</ElementValue>
                <XRef Type="MIM" ID="248600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Maple syrup urine disease (MSUD) is categorized as classic (severe), intermediate, or intermittent. Neonates with classic MSUD are born asymptomatic but without treatment follow a predictable course: 12â€“24 hours. Elevated concentrations of branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) and alloisoleucine, as well as a generalized disturbance of amino acid concentration ratios, are present in blood and the maple syrup odor can be detected in cerumen; Two to three days. Early and nonspecific signs of metabolic intoxication (i.e., irritability, hypersomnolence, anorexia) are accompanied by the presence of branched-chain alpha-ketoacids, acetoacetate, and beta-hydroxybutyrate in urine; Four to six days. Worsening encephalopathy manifests as lethargy, apnea, opisthotonos, and reflexive "fencing" or "bicycling" movements as the sweet maple syrup odor becomes apparent in urine; Seven to ten days. Severe intoxication culminates in critical cerebral edema, coma, and central respiratory failure. Individuals with intermediate MSUD have partial branched-chain alpha-ketoacid dehydrogenase deficiency that manifests only intermittently or responds to dietary thiamine therapy; these individuals can experience severe metabolic intoxication and encephalopathy in the face of sufficient catabolic stress. In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed neonatal manifestations of MSUD remain asymptomatic with continued treatment compliance.</Attribute>
                <XRef ID="NBK1319" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000519087" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528449" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521391" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505096" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529111" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592960" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505125" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561777" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3228" />
                <XRef ID="3228" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301495</ID>
                <ID Source="BookShelf">NBK1319</ID>
              </Citation>
              <Citation Type="general" Abbrev="GMDI/SERC, 2014">
                <ID Source="PubMed">24881969</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="GMDI/SERN, 2021">
                <URL>https://managementguidelines.net/guidelines.php/129/MSUD%20Nutrition%20Guidelines/Version%201.58</URL>
                <CitationText>MSUD Nutrition Management Guidelines</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Leucine, Maple Syrup Urine Disease, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2021">
                <URL>https://www.acmg.net/PDFLibrary/Leucine-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Leucine Elevated, 2021</CitationText>
              </Citation>
              <XRef ID="511" DB="Orphanet" />
              <XRef ID="C0024776" DB="MedGen" />
              <XRef ID="D008375" DB="MeSH" />
              <XRef ID="MONDO:0009563" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS248600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5027791" SubmissionDate="2022-09-14" DateLastUpdated="2022-09-17" DateCreated="2022-09-17">
        <ClinVarSubmissionID localKey="NC_000001.10:g.(?_100652477)_(100661979_100671785)del|MedGen:C0024776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002572045" DateUpdated="2022-09-17" DateCreated="2022-09-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24304607</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33868929</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14508502</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14741190</ID>
          </Citation>
          <Comment>Variant summary: The variant identified by MLPA or other technology involves the deletion of exon 11 (last exon) in the DBT gene. A presumed nomenclature of c.(1281+1_1282-1)_(*9334_?)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result in a large deletion change in the DBT gene, a known mechanism of disease. The variant allele was found at a frequency of 9.1e-05 in 21896 control chromosomes (gnomAD SV and publication data). c.(1281+1_1282-1)_(*9334_?)del has been reported in the literature in multiple compound heterozygous individuals affected with Maple Syrup Urine Disease (Askree_2013, Abadingo_2021). In addition, the variant, also described as DBT (E2) gene 4.7 kb deletion and breakpoints within intron 10 and the 3 non-coding region of the E2 locus (indicating a deletion of exon 11), was found in patients affected with Maple Syrup Urine Disease, including homozygotes (Silao_2004, Chi_2003). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="DBT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.(?_100652477)_(100661979_100671785)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0024776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12061022</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5027791" TraitType="Disease" MappingType="XRef" MappingValue="C0024776" MappingRef="MedGen">
        <MedGen CUI="C0024776" Name="Maple syrup urine disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

